- The FDA has signed off TRACON Pharmaceuticals Inc’s (NASDAQ:TCON) initiation of a Phase 1/2 trial of YH001 in combination with envafolimab and doxorubicin in sarcoma patients, including those who have not received prior therapy.
- The Phase 1/2 trial will assess the safety and efficacy of YH001 and envafolimab in patients with the rare sarcoma subtypes of alveolar soft part sarcoma and chondrosarcoma.
- Related: TRACON Pharma, Eucure Join Forces To Develop CTLA-4 Antibody For Oncology Indications.
- Additionally, the safety and efficacy of YH001, envafolimab, and doxorubicin will be assessed in the more prevalent sarcoma subtypes of leiomyosarcoma and dedifferentiated liposarcoma.
- YH001, an IgG1 antibody against CTLA-4, has shown enhanced antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro.
- Price Action: TCON shares are up 0.50% at $2.02 on the last check Monday.
SunOpta Announces CEO Retirement And Appoints Brian W. Kocher As Successor; Reaffirms Outlook For Q4 2023 And 2024
Reaffirms Outlook for Q4 2023 and 2024SunOpta Inc. ("SunOpta" or the "Company") (NASDAQ:STKL) (TSX:SOY), a U.S.-based global pioneer fueling the future of sustainable, plant-based foods and beverages, today announced the
